A5033477271- Intracranial Aneurysms: Treatment and Complications
- Traumatic Brain Injury and Neurovascular Disturbances
- Blood groups and transfusion
- Platelet Disorders and Treatments
- Antibiotics Pharmacokinetics and Efficacy
- Neurosurgical Procedures and Complications
- Erythrocyte Function and Pathophysiology
- Drug Transport and Resistance Mechanisms
- Congenital Heart Disease Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Hemoglobinopathies and Related Disorders
- Cardiac Arrhythmias and Treatments
- Antimicrobial Resistance in Staphylococcus
- Heparin-Induced Thrombocytopenia and Thrombosis
- Chronic Lymphocytic Leukemia Research
- Cerebrovascular and Carotid Artery Diseases
- Bacterial Identification and Susceptibility Testing
- Cardiac pacing and defibrillation studies
- Epilepsy research and treatment
Medical University of Vienna
2022-2025
2-deoxy-D-glucose is a synthetic glucose analog and potent inhibitor of glycolysis. Preclinical models demonstrated antiviral effects by inducing glucose-deprived state in cells, which interferes with viral replication. This was phase I, first-in-human, double-blind, randomized, placebo-controlled, dose-escalation trial single (cohort 1: 100µl one nostril, cohort 2: 200µl 3: both nostrils) multiple 4: four-times 200µl/day 5: nostrils, 6: six-times nostrils; all for seven days) ascending...
Abstract Background Linezolid exposure in critically ill patients is associated with high inter-individual variability, potentially resulting subtherapeutic antibiotic exposure. exhibits good penetration into the CSF, but its cerebral interstitial fluid (ISF) unknown. Objectives To determine linezolid CSF and ISF of neurointensive care patients. Patients methods Five neurocritical received 600 mg IV twice daily for treatment extracerebral infections. At steady state, blood samples were...
Meropenem is a broad spectrum carbapenem used for the treatment of cerebral infections. There need data describing meropenem pharmacokinetics (PK) in brain tissue to optimize therapy these Here, we present PK model central nervous system and simulate dosing regimens. This was population analysis previously published prospective study patients admitted neurointesive care unit between 2016 2019 who received 2 g intravenously every 8 h. concentration determined blood, cerebrospinal fluid (CSF),...
Introduction: Nimodipine is routinely administered to aneurysmal subarachnoid hemorrhage patients improve functional outcomes. can induce marked systemic hypotension, which might impair cerebral perfusion and brain metabolism. Methods: Twenty-seven having multimodality neuromonitoring oral nimodipine treatment as standard of care were included in this retrospective study. Alterations mean arterial blood pressure (MAP), (CPP), tissue oxygen tension (pbtO 2 ), metabolism (cerebral...
There is accumulating evidence that cerebrospinal fluid (CSF) concentrations of nimodipine correlate with long‐term outcome patients after subarachnoidal hemorrhage (aSAH) by impeding cerebral ischemia. However, pharmacological data on simultaneous serum vs. CSF and intraparenchymal values are rarely reported in larger patient groups. Nimodipine were determined plasma, CSF, interstitial (ISF), at steady state oral (6 × 60 mg/day) intravenous (0.5, 1, 1.5 2 mg/h) administrations 10 aSAH. Area...
Background/Objectives: Digital subtraction angiography (DSA) is the gold standard in diagnosis of cerebral vasospasm, frequently observed after subarachnoid hemorrhage (SAH). However, less-invasive methods, such as computed tomography (CTA), may be equally accurate. To further clarify comparability, this study evaluated reliability CTA detecting vasospasm. Methods: This retrospective included 51 patients with SAH who underwent both and DSA within 24 h. The smallest diameter proximal arterial...
Introduction Although rituximab is approved for several autoimmune diseases, no formal dose finding studies have been conducted. The amount of CD20+ cells differs significantly between diseases and B-cell malignancies. Hence, requirements anti-CD20 therapies may differ accordingly. Methods We conducted a phase II pilot trial investigating the effects safety very low doses rituximab, i.e., 5 mg/m 2 every 3 weeks, 20 mg 4 50 months ( n = each) 100 1) in patients with hemolytic anemia (AIHA) to...
Background: Predicting the probability for sudden cardiac death (SCD) and thus evaluation of patients electrical device therapy and/or ablation is one main tasks in clinics adults with congenital heart dise... | Find, read cite all research you need on Tech Science Press